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Update: Clostridium novyi  and Unexplained Illness
Among Injecting-Drug Users — Scotland, Ireland, and England,
April–June 2000
Since April 19, 2000, health authorities in Scotland, Ireland, England, and the United
States have been investigating an outbreak of unexplained illness and death among
injecting-drug users (IDUs) in the United Kingdom and Ireland (1–3 ). Initial testing of
specimens from 76 IDUs identified Clostridium  species in 18 (24%) patients; nine were
Clostridium novyi. This report updates the investigation of this outbreak, which indicates
that Clostridium  species may be associated with these illnesses.
During April 1–June 19, investigators identified 88 IDUs in Scotland (n=48), Ireland
(n=19), and England (n=21) with injection-site soft tissue inflammation resulting in hospi-
talization or death; 40 (45%) have died. Thirty-five (40%) patients had illnesses that met
the syndrome-based case-definition (1 ), including sustained hypotension and markedly
elevated white blood cell count (WBC), or postmortem evidence of a diffuse toxic or
infectious process, with initial hospitalization during April 11–June 6 (Figure 1). The me-
dian age of the 35 case-patients was 32 years (range: 20–51 years); 18 (51%) were men,
and 34 (97%) died. Median peripheral WBC was 63,600 cells/mm3 (range: 8,200–153,000
cells/mm3). In Ireland, cases remained limited to Dublin, and in Scotland cases have been
reported from both the Glasgow and Aberdeen areas. In England, most cases have been
identified in and around Manchester, but several cases have been reported from other
parts of the country.
FIGURE 1. Cases of unexplained severe illness and death among injecting drug users —
Scotland, Ireland, and England, April–June 2000
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Unexplained Illness Among Injecting-Drug Users — Continued
Among the 35 patients with illnesses meeting the case definition, nine (26%) have
laboratory evidence of clostridial infections based on culture isolation or 16S ribosomal
DNA polymerase chain reaction and sequencing performed on blood or tissue, including
three C. novyi, three C. perfringens, one with both C. novyi  and C. perfringens, and two
clostridial species awaiting further typing. Of the remaining 41 patients with illnesses
who failed to meet the case definition but who may be linked to this outbreak, and for
whom data are available, nine (22%) have evidence of clostridial infections, including
five C. novyi and four with species pending. Although the role of other pathogens re-
quires further delineation, only four (11%) patients with illnesses meeting the case defi-
nition have evidence of other etiologic agents (Staphylococcus aureus, group A Strepto-
coccus, and group C Streptococcus), compared with 12 (29%) of 41 patients with unex-
plained soft tissue infections but lacking severe systemic toxicity.
Reported by: S Ahmed, MD, L Gruer, MD, C McGuigan, MD, G Penrice, MD, K Roberts, MPhil,
Dept of Public Health, Greater Glasgow Health Board; J Hood, MD, Dept of Microbiology,
Glasgow Royal Infirmary; P Redding, MD, Dept of Microbiology, Victoria Infirmary Glasgow;
G Edwards, MD, Stobhill General Hospital; M Black, MD, J McFarlane, MD, Dept of Forensic
Pathology, Univ of Glasgow; D Cromie, MD, Dept of Public Health, Lanarkshire Health Board;
H Howie, MD, Dept of Public Health, Grampian Health Board; A Leonard, MD, Dept of Microbi-
ology, Monklands Hospital; D Goldberg, MD, A Taylor, PhD, S Hutchinson, MSc, K Roy, PhD,
S Wadd, PhD, R Andraghetti, MD (EPIET), Scottish Center for Infection and Environmental
Health, Glasgow, Scotland. J Barry, MD, G Sayers, MD, M Cronin, MD, T O’Connell, MD, M Ward,
MD, P O’Sullivan, MD, B O’Herlihy, MD, Eastern Regional Health Authority, Dept of Public
Health; E Keenan, MD, J O’Connor, MD, L Mullen, MSc, B Sweeney, MD, Eastern Regional Health
Authority Area Health Boards’ Drug Svcs; D O’Flanagan, MD, D Igoe, MD, National Disease
Surveillance Center; C Bergin, MD, S O’Briain, MD, C Keane, MD, E Mulvihill, MD, P Plunkett, MD,
G McMahon, MD, T Boyle, MD, S Clarke, MD, St. James’s Hospital; E Leen, MD, James Connolly
Memorial Hospital; M Cassidy, MD, State Pathology Svc, Dublin, Ireland. T Djuretic, MD, N Gill,
MD, V Hope, PhD, J Jones, MD, G Nichols, PhD, A Weild, MPhil, Public Health Laboratory Svc
(PHLS) Communicable Disease Surveillance Centre; R George, MD, PHLS Respiratory and
Systemic Infection Laboratory; P Borriello, PhD, PHLS Central Public Health Laboratory, Lon-
don, England; J Brazier, PhD, J Salmon, MD, PHLS Anaerobe Reference Unit, Cardiff, Wales;
N Lightfoot, MD, PHLS North, Newcastle; A Roberts, PhD, Centre for Applied Microbiology and
Research, Porton Down, England. Infectious Diseases Pathology Activity, Div of Viral and
Rickettsial Diseases; Bioterrorism Preparedness and Response Program; Meningitis and Spe-
cial Pathogens Br, Div of Bacterial and Mycotic Diseases, National Center for Infectious Dis-
eases; and EIS officers, CDC.
Editorial Note: Although clostridial species have been implicated previously in clusters
of wound infections among IDUs (4,5 ), the number of cases and severity of illness
associated with this outbreak appear to be unique. C. perfringens  can produce fulminant
shock through direct toxogenic effects on myocardial contractility, but this organism
usually causes extensive tissue destruction and gas production, features that are not
prominent in the current cases (6 ). C. sordellii  can also cause a distinctive, toxin-mediated
illness characterized by tissue edema, myonecrosis, leukemoid reaction and sudden
onset of shock (7 ). However, perhaps because of its fastidious and strict anaerobic
growth requirements (6 ), C. novyi  has been less commonly implicated in such a clinical
syndrome. The significance of isolating clostridial species from the tissue of the patients
described in this report remains unclear, but the presence of these organisms suggests
soil or fecal contamination of the drugs or other materials used by these IDUs and may
provide the causative explanation for their illnesses.
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Unexplained Illness Among Injecting-Drug Users — Continued
Clinical, epidemiologic, and laboratory investigations continue to characterize these
illnesses, confirm the role of C. novyi  as one of the potential etiologic agents, identify risk
factors for disease, and implement measures to prevent further cases. Surveillance
activities to identify additional cases in the United Kingdom and Ireland are ongoing, and
efforts to find cases in the rest of Europe or the United States have been expanded.
Health-care providers and public health personnel are encouraged to report persons
with illnesses meeting the case definition to their designated public health authorities.
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Notice to Readers
Injuries From Fireworks in the United States
Fireworks traditionally are used in the United States to celebrate Independence Day
on July 4th. The U.S. Consumer Product Safety Commission (CPSC) estimates that
8500 persons in the United States are treated in emergency departments each year for
fireworks-related injuries (1 ). Of all fireworks-related injuries, 70%–75% occur during a
30-day period that surrounds the July 4th holiday (June 23–July 23) (2 ). Seven of every
100 persons injured by fireworks are hospitalized, approximately 40% of those injured
are children aged 14 years, and males are injured three times more often than females
(1 ). The injury rate is highest among boys aged 10–14 years (3 ). Most commonly, injuries
from fireworks affect the hands (34%), face (12%), and eyes (17%) (4 ). Injuries are more
frequent and more severe among persons who are active participants than among by-
standers (3 ).
The estimated annual cost of fireworks-related injuries is $100 million (4 ). In 1997,
the U.S. National Fire Protection Association (NFPA) estimated that fireworks were re-
sponsible for direct property damage of $22.7 million (5 ).
Although some types of fireworks are legal in some states, CDC, NFPA, and CPSC
recommend that fireworks be used only by professionals. All fireworks potentially are
dangerous (e.g., sparklers burn at more than 1000 F [538 C]), especially to children.
